Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

VERTEX PHARMACEUTICALS INC / MA : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2019 | 04:48pm EDT

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On July 25, 2019, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release announcing Dr. Jeffrey M. Leiden's upcoming transition to the role of Executive Chairman and the Company's appointment of Reshma Kewalramani, M.D., as our President and Chief Executive Officer effective April 1, 2020.

Effective as of March 31, 2020, Dr. Leiden will cease to be President and Chief Executive Officer of the Company, and, effective April 1, 2020, Dr. Kewalramani, 46, now the Company's Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, will become the Company's next President and Chief Executive Officer and will be appointed to serve on the Company's board of directors (the "Board"). For additional biographical information on Dr. Kewalramani, please see the Company's Form 10-K filed with the Securities and Exchange Commission on February 13, 2019. There are no transactions between Dr. Kewalramani and the Company that are required to be disclosed under Item 404(a) of Regulation S-K.

Dr. Leiden has agreed to continue to serve the Company as its Executive Chairman and will, subject to his continuing re-election by the Company's shareholders, continue to serve on the Board, and as Chairman of the Board.

In connection with the announcement of Dr. Kewalramani's promotion, the Management Development and Compensation Committee of the Board increased her base salary to $800,000. In addition, the Company entered into a new employment agreement and a new change of control agreement with Dr. Kewalramani, each of which will be effective upon Dr. Kewalramani's appointment to the role of President and Chief Executive Officer on April 1, 2020. The employment agreement provides for Dr. Kewalramani to receive a base salary of $1,150,000 and a target annual bonus of 120% of base salary, and for Dr. Kewalramani's continued participation in our equity programs applicable to the Company's senior executives. The first equity awards made after the effective date of the employment agreement are expected to be approved by the Board and our Management Development and Compensation Committee during the first calendar quarter of 2021 with an aggregate target grant date fair value of $11,000,000. The employment agreement also provides that if Dr. Kewalramani terminates her employment for good reason or if we terminate her employment without cause, including such a termination of employment occurring prior to April 1, 2020, she will be entitled to receive (i) an amount equal to 200% of her base salary and target annual bonus, (ii) a pro-rated portion of the target annual bonus for the year in which her employment terminates, (iii) Company payment of medical, dental and life insurance premiums for 18 months following termination, and (iv) 12 months' accelerated vesting of her outstanding equity awards (with any applicable performance vesting criteria being deemed achieved at target). If Dr. Kewalramani's employment is terminated due to her death or disability, she will be entitled to receive (i) a pro-rated annual bonus (based on actual performance) for the year in which the termination of employment occurs, and (ii) consistent with programs applicable to all of the Company's employees, accelerated vesting of all of her outstanding options and restricted stock unit awards (with any applicable performance vesting criteria being deemed achieved at target). Pursuant to the change of control agreement, if we terminate Dr. Kewalramani's employment without cause on a date within 90 days prior to or 12 months after a change of control or if Dr. Kewalramani terminates her employment for good reason as a result of an event constituting good reason that occurs on a date within 90 days prior to or 12 months after a change of control, Dr. Kewalramani will receive (i) an amount equal to 299% of her base salary and target annual bonus, (ii) a pro-rated portion of the target annual bonus for the year in which her employment terminates, and (iii) full vesting of all of her outstanding equity awards (with any applicable performance vesting criteria being deemed achieved at target).

Dr. Kewalramani's current employment agreement and change of control agreement will each expire and be terminated effective upon her appointment to the role of President and Chief Executive Officer on April 1, 2020.

In connection with the leadership transition, the Company also entered into an amendment to the amended and restated employment agreement by and between Dr. Leiden and the Company, dated November 30, 2016, to reflect the parties' agreement not to extend the term of such employment agreement beyond March 31, 2020, and to enter into a new employment agreement, attached as an exhibit to the amendment, to govern the terms and conditions of Dr. Leiden's employment as Executive Chairman effective as of April 1, 2020. Dr. Leiden's employment as President and Chief Executive Officer of the Company will terminate upon the expiration of the term of his current agreement on March 31, 2020, and pursuant to the terms of his current agreement, he will be entitled to equity acceleration resulting from the expiration of the term of his employment agreement. The amendment also provides that if Dr. Leiden's employment is terminated by the Company without cause prior to the expiration of his current agreement, Dr. Leiden will be entitled to an additional severance payment equal to the severance payment payable under his new employment agreement in the event of the termination of his employment without cause or by him for good reason, as described below.

--------------------------------------------------------------------------------

The new employment agreement that the Company and Dr. Leiden have agreed to enter into in respect of his service as the Company's Executive Chairman will have a three-year term ending March 31, 2023. During the first year of his term as Executive Chairman, Dr. Leiden will be entitled to a reduced base salary of $1,000,000 and a reduced target annual bonus of 100% of base salary, and will not receive any base salary or annual bonus for the next two years of the term. In respect of each year during the term of the agreement, Dr. Leiden will be entitled to receive annual equity awards, 50% of which will be subject to performance-based vesting terms, which annual equity awards will have an aggregate grant date value of $9,000,000, $8,500,000 and $6,500,000, respectively. In the event that Dr. Leiden's employment is terminated by the Company without cause or by him for good reason prior to the expiration of the three-year term, he will be entitled to receive Company payment of medical, dental and life insurance premiums for, and to a severance payment in an amount equal to any base salary or annual bonus amounts remaining unpaid under the agreement, and a cash payment equal to the grant date value of each of the annual equity awards he would have received under the agreement following the date of termination had his employment continued through the end of the term. If Dr. Leiden's employment under the term of his new agreement is terminated due to his death or disability prior to the expiration of the three-year term, he will be entitled to any base salary or annual bonus amounts remaining unpaid under the agreement and to a cash payment equal to the grant date value of the next annual equity award he would have received on the grant date immediately following the date of termination had his employment continued through such date.

Any severance payments or benefits provided for under the agreements described above are conditioned on Dr. Leiden's or Dr. Kewalramani's, as applicable, timely execution of a release of claims in favor of the Company. Dr. Leiden and Dr. Kewalramani are also each parties to separate non-disclosure, non-competition and inventions assignment agreements with the Company that impose restrictive covenants in favor of the Company on the executive both during and after employment with the Company.

The foregoing description of the agreements with Dr. Kewalramani and Dr. Leiden does not purport to be complete and is qualified in its entirety by reference to the full text of such agreements, which are filed as Exhibit 10.1 through 10.3 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

  Exhibit
   No.                                            Description
10.1              Employment Agreement, dated as of July 24, 2019, between Vertex
                Pharmaceuticals Incorporated and Reshma Kewalramani
10.2              Change of Control Agreement, dated as of July 24, 2019, between Vertex
                Pharmaceuticals Incorporated and Reshma Kewalramani
                  Amendment No. 1, dated as of July 24, 2019, to the Amended and Restated
10.3            Employment Agreement, dated November 30, 2016, by and between Vertex
                Pharmaceuticals Incorporated and Jeffrey M. Leiden, M.D., PhD.



--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS
09/13VERTEX PHARMACEUTICALS : Announces New Access Agreement with Scottish Government..
AQ
09/12VERTEX PHARMACEUTICALS : Announces New Access Agreement with Scottish Government..
BU
09/10VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Global Healthcare Conf..
BU
09/03VERTEX PHARMACEUTICALS : to Acquire Semma Therapeutics With a Goal of Developing..
BU
08/21VERTEX PHARMACEUTICALS : FDA Accepts New Drug Application for VX-445, Tezacaftor..
AQ
08/20VERTEX PHARMACEUTICALS : FDA Accepts New Drug Application for VX-445 (Elexacafto..
BU
08/01VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
AQ
07/31VERTEX : 2Q Earnings Snapshot
AQ
07/31VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
AQ
07/31VERTEX PHARMACEUTICALS : Reports Second-Quarter 2019 Financial Results
BU
More news